Jolien Tol


Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands


  1. Tol J, Dijkstra J, Vink Börger M, Nagtegaal I, Punt C, van Krieken J, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. 2010;14:2122-31 pubmed publisher
    ..5% (95% confidence interval [CI] 91.7-97.9%) and 96.5% (95% CI 93.0-98.6%), respectively. The real-time PCR based assay is the method of choice in samples with a tumour cell percentage below 30%. ..
  2. Mekenkamp L, Tol J, Dijkstra J, de Krijger I, Vink Börger M, van Vliet S, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012;12:292 pubmed publisher
    ..Our results indicate that the assessment of KRAS CNA and miRNAs targeting KRAS might further optimize the selection of mCRC eligible for anti-EGFR therapy. ..